You are here

Biological Therapeutics

From patented antibodies to tumour-associated cell surface markers, we have a diverse portfolio of agents from pre-clinical to phase 1 clinical development available for collaborative development and/or licensing.

These three technologies offer a platform of novel CAR-T cell enhancements for improving CAR-T persistence in the tumor microenvironment.

Read more

We have developed a first-in-class, therapeutic-quality antibody that inhibits human Arginase-2 and are seeking a partner with interest in arginase in tumour immunosuppression and other areas.

Read more

Licensing opportunity around FcɣR-independent “super-agonistic” 4-IBB mABs containing a propriety hinge technology that induces CD8+ T cell activation and intratumoral Treg cell depletion.

Read more

We are seeking a partner experienced in the field of cell therapy development and in the Chinese regulatory environment to take this technology through to first in man trials in China.

Read more

CRUK is seeking an industry partner for co-development and/or exclusive licensing of its CLEC14A IP, materials and know-how, to progress anti-CLEC14A antibodies into first-in-human clinical studies

Read more

Pages